

Title (en)

COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3

Title (de)

KOMBINATIONSTHERAPIEN MIT ANTIKÖRPERMOLEKÜLEN GEGEN LAG-3

Title (fr)

POLYTHÉRAPIES COMPRENANT DES MOLÉCULES D'ANTICORPS DIRIGÉES CONTRE LAG-3

Publication

**EP 3964528 A1 20220309 (EN)**

Application

**EP 21165292 A 20160728**

Priority

- US 201562198492 P 20150729
- EP 16757391 A 20160728
- US 2016044545 W 20160728

Abstract (en)

Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

IPC 8 full level

**C07K 16/28** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP US)

**A61P 35/00** (2017.12 - EP); **C07K 16/2803** (2013.01 - EP US); **C07K 2317/24** (2013.01 - EP US); **C07K 2317/76** (2013.01 - EP US); **C07K 2317/92** (2013.01 - EP US)

Citation (applicant)

- US 2015259420 A1 20150917 - TRIEBEL FRÉDÉRIC [FR], et al
- US 201514657260 A 20150313
- WO 9404678 A1 19940303 - CASTERMAN CECILE [BE], et al
- US 5223409 A 19930629 - LADNER ROBERT C [US], et al
- WO 9218619 A1 19921029 - SCRIPPS RESEARCH INST [US]
- WO 9117271 A1 19911114 - AFFYMAX TECH NV [NL]
- WO 9220791 A1 19921126 - CMABRIDGE ANTIBODY TECH [GB], et al
- WO 9215679 A1 19920917 - PROTEIN ENG CORP [US]
- WO 9301288 A1 19930121 - DEUTSCHES KREBSFORSCH [DE]
- WO 9201047 A1 19920123 - CAMBRIDGE ANTIBODY TECH [GB], et al
- WO 9209690 A2 19920611 - GENENTECH INC [US]
- WO 9002809 A1 19900322 - PROTEIN ENG CORP [US]
- WO 9100906 A1 19910124 - GENETICS INST [US]
- WO 9110741 A1 19910725 - CELL GENESYS INC [US]
- WO 9203918 A1 19920319 - GENPHARM INT [US]
- WO 9203917 A1 19920319 - GENPHARM INT [US]
- US 8602269 W 19861027
- EP 0184187 A2 19860611 - TEIJIN LTD [JP]
- EP 0171496 A2 19860219 - JAPAN RES DEV CORP [JP]
- EP 0173494 A2 19860305 - UNIV LELAND STANFORD JUNIOR [US]
- WO 8601533 A1 19860313 - CELLTECH LTD [GB]
- US 4816567 A 19890328 - CABILLY SHMUEL [US], et al
- EP 0125023 A1 19841114 - GENENTECH INC [US], et al
- US 5585089 A 19961217 - QUEEN CARY L [US], et al
- US 5693761 A 19971202 - QUEEN CARY L [US], et al
- US 5693762 A 19971202 - QUEEN CARY L [US], et al
- US 5225539 A 19930706 - WINTER GREGORY P [GB]
- GB 2188638 A 19871007 - WINTER GREGORY PAUL
- EP 0519596 A1 19921223 - MERCK & CO INC [US], et al
- EP 0388151 A1 19900919 - CELLTECH LTD [GB]
- US 5624821 A 19970429 - WINTER GREGORY P [GB], et al
- US 5648260 A 19970715 - WINTER GREGORY PAUL [GB], et al
- US 5208020 A 19930504 - CHARI RAVI J [US], et al
- US 5475092 A 19951212 - CHARI RAVI V J [US], et al
- US 5585499 A 19961217 - CHARI RAVI V J [US], et al
- US 5846545 A 19981208 - CHARI RAVI V J [US], et al
- US 5731168 A 19980324 - CARTER PAUL J [US], et al
- WO 2009089004 A1 20090716 - AMGEN INC [US], et al
- WO 2006106905 A1 20061012 - CHUGAI PHARMACEUTICAL CO LTD [JP], et al
- WO 2010129304 A2 20101111 - ONCOMED PHARM INC [US], et al
- WO 2007110205 A2 20071004 - MERCK PATENT GMBH [DE], et al
- WO 2008119353 A1 20081009 - GENMAB AS [DK], et al
- WO 2011131746 A2 20111027 - GENMAB AS [DK], et al
- WO 2013060867 A2 20130502 - GENMAB AS [DK], et al
- US 4433059 A 19840221 - CHANG CHI-DEU [US], et al
- US 4444878 A 19840424 - PAULUS HENRY P [US]
- US 5273743 A 19931228 - AHLEM CLARENCE [US], et al
- US 5534254 A 19960709 - HUSTON JAMES S [US], et al
- US 5582996 A 19961210 - CURTIS PETER J [US]
- US 5591828 A 19970107 - BOSSLET KLAUS [DE], et al
- US 5635602 A 19970603 - CANTOR CHARLES R [US], et al

- US 5637481 A 19970610 - LEDBETTER JEFFREY A [US], et al
- US 5837242 A 19981117 - HOLLIGER KASPAR-PHILIPP [GB], et al
- US 5837821 A 19981117 - WU ANNA M [US]
- US 5844094 A 19981201 - HUDSON PETER JOHN [AU], et al
- US 5864019 A 19990126 - KING DAVID JOHN [GB], et al
- US 5869620 A 19990209 - WHITLOW MARC D [US], et al
- US 5910573 A 19990608 - PLUECKTHUN ANDREAS [DE], et al
- US 5932448 A 19990803 - TSO J YUN [US], et al
- US 5959083 A 19990928 - BOSSLET KLAUS [DE], et al
- US 5989830 A 19991123 - DAVIS PAUL JAMES [GB], et al
- US 6005079 A 19991221 - CASTERMAN CECILE [BE], et al
- US 6239259 B1 20010529 - DAVIS PAUL J [GB], et al
- US 6294353 B1 20010925 - PACK PETER [DE], et al
- US 6333396 B1 20011225 - FILPULA DAVID R [US], et al
- US 6476198 B1 20021105 - KANG ANGRAY SINGH [US]
- US 6511663 B1 20030128 - KING DAVID JOHN [GB], et al
- US 6670453 B2 20031230 - FRENKEN LEON GERARDUS [NL], et al
- US 6743896 B2 20040601 - FILPULA DAVID [US], et al
- US 6809185 B1 20041026 - SCHOONJANS REINHILDE [BE], et al
- US 6833441 B2 20041221 - WANG CAILI [US], et al
- US 7129330 B1 20061031 - LITTLE MELVYN [DE], et al
- US 7183076 B2 20070227 - ARATHOON W ROBERT [US], et al
- US 7521056 B2 20090421 - CHANG CHIEN HSING [US], et al
- US 7527787 B2 20090505 - CHANG CHIEN-HSING [US], et al
- US 7534866 B2 20090519 - CHANG CHIEN HSING [US], et al
- US 7612181 B2 20091103 - WU CHENGBIN [US], et al
- US 2002004587 A1 20020110 - MILLER KATHY L [US], et al
- US 2002076406 A1 20020620 - LEUNG SHUI-ON [HK]
- US 2002103345 A1 20020801 - ZHU ZHENPING [US]
- US 2003207346 A1 20031106 - ARATHOON WILLIAM R [US], et al
- US 2003211078 A1 20031113 - HEAVNER GEORGE A [US]
- US 2004219643 A1 20041104 - WINTER GREG [GB], et al
- US 2004220388 A1 20041104 - MERTENS NICO [BE], et al
- US 2004242847 A1 20041202 - FUKUSHIMA NAOSHI [JP], et al
- US 2005003403 A1 20050106 - ROSSI EDMUND A [US], et al
- US 2005004352 A1 20050106 - KONTERMANN ROLAND [DE], et al
- US 2005069552 A1 20050331 - BLECK GREGORY T [US], et al
- US 2005079170 A1 20050414 - LE GALL FABRICE [DE], et al
- US 2005100543 A1 20050512 - HANSEN HANS J [US], et al
- US 2005136049 A1 20050623 - LEDBETTER JEFFREY A [US], et al
- US 2005136051 A1 20050623 - SCALLON BERNARD [US]
- US 2005163782 A1 20050728 - GLASER SCOTT [US], et al
- US 2005266425 A1 20051201 - ZAUDERER MAURICE [US], et al
- US 2006083747 A1 20060420 - WINTER GREGORY P [GB], et al
- US 2006120960 A1 20060608 - DEYEV SERGEY [RU], et al
- US 2006204493 A1 20060914 - HUANG ARTHUR J [US], et al
- US 2006263367 A1 20061123 - FEY GEORG H [DE], et al
- US 2007004909 A1 20070104 - JOHNSON LESLIE S [US], et al
- US 2007087381 A1 20070419 - KOJIMA TETSUO [JP]
- US 2007128150 A1 20070607 - NORMAN TIMOTHY J [GB]
- US 2007141049 A1 20070621 - BREDEHORST REINHARD [DE], et al
- US 2007154901 A1 20070705 - THOGERSEN HANS C [DK], et al
- US 2007274985 A1 20071129 - DUBEL STEFAN [DE], et al
- US 2008050370 A1 20080228 - GLASER SCOTT [US], et al
- US 2008069820 A1 20080320 - FUH GERMAINE [US], et al
- US 2008152645 A1 20080626 - PARDRIDGE WILLIAM M [US], et al
- US 2008171855 A1 20080717 - ROSSI EDMUND A [US], et al
- US 2008241884 A1 20081002 - SHITARA KENYA [JP], et al
- US 2008254512 A1 20081016 - CAPON DANIEL J [US]
- US 2008260738 A1 20081023 - MOORE MARGARET D [US], et al
- US 2009130106 A1 20090521 - CHRISTOPHERSON RICHARD IAN [AU], et al
- US 2009148905 A1 20090611 - ASHMAN CLAIRE [GB], et al
- US 2009155275 A1 20090618 - WU HERREN [US], et al
- US 2009162359 A1 20090625 - KLEIN CHRISTIAN [DE], et al
- US 2009162360 A1 20090625 - KLEIN CHRISTIAN [DE], et al
- US 2009175851 A1 20090709 - KLEIN CHRISTIAN [DE], et al
- US 2009175867 A1 20090709 - THOMPSON PETER A [US], et al
- US 2009232811 A1 20090917 - KLEIN CHRISTIAN [DE], et al
- US 2009234105 A1 20090917 - GERVAY-HAGUE JACQUELYN [US], et al
- US 2009263392 A1 20091022 - IGAWA TOMOYUKI [JP], et al
- US 2009274649 A1 20091105 - QU ZHENGXING [US], et al
- EP 0346087 A2 19891213 - SNOW BRAND MILK PROD CO LTD [JP]
- WO 0006605 A2 20000210 - MICROMET GES FUER BIOMEDIZINIS [DE], et al
- WO 02072635 A2 20020919 - UNIV LONDON [GB], et al
- WO 2004081051 A1 20040923 - UNIV BIRMINGHAM [GB], et al
- WO 2006020258 A2 20060223 - IMCLONE SYSTEMS INC [US], et al
- WO 2007044887 A2 20070419 - TRANSTARGET INC [US], et al
- WO 2007095338 A2 20070823 - IMCLONE SYSTEMS INC [US], et al
- WO 2007137760 A2 20071206 - BAYER SCHERING PHARMA AG [DE], et al
- WO 2008119353 A1 20081009 - GENMAB AS [DK], et al
- WO 2009021754 A2 20090219 - BAYER SCHERING PHARMA AG [DE], et al
- WO 2009068630 A1 20090604 - ABLYNX NV [BE], et al
- WO 9103493 A1 19910321 - UNIV SOUTHAMPTON [GB]

- WO 9323537 A1 19931125 - CREATIVE BIOMOLECULES INC [US], et al
- WO 9409131 A1 19940428 - SCOTGEN LTD [GB], et al
- WO 9412625 A2 19940609 - ZENECA LTD [GB]
- WO 9509917 A1 19950413 - UNIV CALIFORNIA [US]
- WO 9637621 A2 19961128 - MORPHOSYS PROTEINOPTIMIERUNG [DE], et al
- WO 9964460 A1 19991216 - CELLTECH THERAPEUTICS LTD [GB], et al
- US 2015056224 A1 20150226 - DUBENSKY JR THOMAS W [US], et al
- WO 2014189805 A1 20141127 - AURO BIOTECH INC [US], et al
- WO 2014189806 A1 20141127 - ADURO BIOTECH INC [US]
- US 2015056225 A1 20150226 - RUSSELL DAVID W [US]
- WO 2004060319 A2 20040722 - 3M INNOVATIVE PROPERTIES CO [US]
- WO 2014012479 A1 20140123 - SHANGHAI BIRDIE BIOTECH INC [CN]
- EP 0296122 A2 19881221 - SANDOZ AG [CH], et al
- WO 2007030377 A1 20070315 - NOVARTIS AG [CH], et al
- WO 02066470 A1 20020829 - AMGEN INC
- US 6884879 B1 20050426 - BACA MANUEL [US], et al
- WO 2005012359 A2 20050210 - GENENTECH INC [US], et al
- WO 2005044853 A2 20050519 - GENENTECH INC [US], et al
- US 7060269 B1 20060613 - BACA MANUEL [US], et al
- US 6582959 B2 20030624 - KIM KYUNG JIN [US]
- US 6703020 B1 20040309 - THORPE PHILIP E [US], et al
- US 6054297 A 20000425 - CARTER PAUL J [US], et al
- WO 9845332 A2 19981015 - GENENTECH INC [US], et al
- WO 9630046 A1 19961003 - GENENTECH INC [US]
- WO 9410202 A1 19940511 - GENENTECH INC [US]
- EP 0666868 B1 20020403 - GENENTECH INC [US]
- US 2006009360 A1 20060112 - PIFER ROBERT [US], et al
- US 2005186208 A1 20050825 - FYFE GWENDOLYN [US], et al
- US 2003206899 A1 20031106 - FERRARA NAPOLEONE [US], et al
- US 2003190317 A1 20031009 - BACA MANUEL [AU], et al
- US 2003203409 A1 20031030 - KIM KYUNG JIN [US]
- US 2005112126 A1 20050526 - BACA MANUEL [US], et al
- US 7767675 B2 20100803 - ZHUO JINCONG [US], et al
- US 8420645 B2 20130416 - WENG LINGKAI [US], et al
- WO 2006086469 A2 20060817 - LEDBETTER STEVEN R [US], et al
- US 8383780 B2 20130226 - LEDBETTER STEVEN R [US], et al
- US 8591901 B2 20131126 - LEDBETTER STEVEN R [US], et al
- WO 2012167143 A1 20121206 - XOMA TECHNOLOGY LTD [US], et al
- US 2010178684 A1 20100715 - WOO SAVIO L C [US], et al
- US 8591881 B2 20131126 - PALESE PETER [US], et al
- US 2012122185 A1 20120517 - PALESE PETER [US], et al
- US 2014271677 A1 20140918 - PALESE PETER [US], et al
- WO 2007070660 A2 20070621 - HARVARD COLLEGE [US], et al
- WO 2012167230 A1 20121206 - HARVARD COLLEGE [US], et al
- EP 1960009 B1 20111123 - HARVARD COLLEGE [US], et al
- US 8067237 B2 20111129 - MOONEY DAVID J [US], et al
- US 8932583 B2 20150113 - MOONEY DAVID J [US], et al
- US 2011020216 A1 20110127 - MOONEY DAVID JAMES [US], et al
- WO 2009102465 A2 20090820 - HARVARD COLLEGE [US], et al
- WO 2013106852 A1 20130718 - HARVARD COLLEGE [US], et al
- WO 2013158673 A1 20131024 - HARVARD COLLEGE [US]
- WO 2012048165 A2 20120412 - HARVARD COLLEGE [US], et al
- WO 2012149358 A1 20121101 - HARVARD COLLEGE [US], et al
- US 6111090 A 20000829 - GORMAN DANIEL M [US], et al
- EP 0920505 B1 20080604 - SCHERING CORP [US]
- US 8586023 B2 20131119 - SHIKU HIROSHI [JP], et al
- WO 2010003118 A1 20100107 - TRUBION PHARMACEUTICALS INC [US], et al
- WO 2011090754 A1 20110728 - EMERGENT PRODUCT DEV SEATTLE [US], et al
- US 7025962 B1 20060411 - GORMAN DANIEL M [US], et al
- EP 1947183 B1 20130717 - MERCK SHARP & DOHME [US]
- US 7812135 B2 20101012 - SMITH L MARY [US], et al
- US 8388967 B2 20130305 - SMITH L MARY [US], et al
- US 8591886 B2 20131126 - PONATH PAUL [US], et al
- EP 1866339 A2 20071219 - TOLERRX INC [US]
- WO 2011028683 A1 20110310 - SCHERING CORP [US], et al
- US 8709424 B2 20140429 - SCHEBYE XIAO MIN [US], et al
- WO 2013039954 A1 20130321 - SANOFI SA [FR], et al
- US 2014072566 A1 20140313 - KWON BYOUNG SE [KR]
- WO 2015026684 A1 20150226 - MERCK SHARP & DOHME [US], et al
- WO 2005007190 A1 20050127 - SCHERING CORP [US], et al
- WO 2007133822 A1 20071122 - GENZYME CORP [US], et al
- WO 2005055808 A2 20050623 - GENZYME CORP [US], et al
- WO 9940196 A1 19990812 - GENENTECH INC [US]
- WO 0103720 A2 20010118 - GENENTECH INC [US]
- WO 9920758 A1 19990429 - HUMAN GENOME SCIENCES INC [US], et al
- US 6689607 B2 20040210 - NI JIAN [US], et al
- WO 2006083289 A2 20060810 - UNIV DUKE [US], et al
- WO 2005115451 A2 20051208 - ISIS INNOVATION [GB], et al
- US 7618632 B2 20091117 - COLLINS MARY [US], et al
- WO 2011051726 A2 20110505 - ISIS INNOVATION [GB], et al
- US 2015210769 A1 20150730 - FREEMAN GORDON JAMES [US], et al
- US 201514604415 A 20150123
- US 2015210769 A1 20150730 - FREEMAN GORDON JAMES [US], et al

- US 8008449 B2 20110830 - KORMAN ALAN J [US], et al
- WO 2006121168 A1 20061116 - ONO PHARMACEUTICAL CO [JP], et al
- US 8354509 B2 20130115 - CARVEN GREGORY JOHN [US], et al
- WO 2009114335 A2 20090917 - MERCK & CO INC [US], et al
- WO 2009101611 A1 20090820 - CURETECH LTD [IL], et al
- US 8609089 B2 20131217 - LANGERMANN SOLOMON [US], et al
- US 2010028330 A1 20100204 - COLLINS MARY [US], et al
- US 2012114649 A1 20120510 - LANGERMANN SOLOMON [US], et al
- WO 2010027827 A2 20100311 - AMPLIMMUNE INC [US], et al
- WO 2011066342 A2 20110603 - AMPLIMMUNE INC [US], et al
- US 2016108123 A1 20160421 - FREEMAN GORDON JAMES [US], et al
- US 201514881888 A 20151013
- US 2016108123 A1 20160421 - FREEMAN GORDON JAMES [US], et al
- WO 2013079174 A1 20130606 - MERCK PATENT GMBH [DE]
- WO 2010077634 A1 20100708 - GENENTECH INC [US], et al
- WO 2007005874 A2 20070111 - MEDAREX INC [US], et al
- US 7943743 B2 20110517 - KORMAN ALAN J [US], et al
- WO 2013019906 A1 20130207 - GENENTECH INC [US], et al
- US 2012039906 A1 20120216 - OLIVE DANIEL [FR]
- WO 2011066389 A1 20110603 - MEDIMMUNE LTD [GB], et al
- WO 2015036499 A1 20150319 - MEDIMMUNE LTD [GB]
- US 2015218274 A1 20150806 - SABATOS-PEYTON CATHERINE ANNE [US], et al
- US 201514610837 A 20150130
- US 2015218274 A1 20150806 - SABATOS-PEYTON CATHERINE ANNE [US], et al
- US 8552156 B2 20131008 - TAKAYANAGI SHIN-ICHIRO [JP], et al
- WO 2011155607 A1 20111215 - KYOWA HAKKO KIRIN CO LTD [JP], et al
- EP 2581113 A1 20130417 - KYOWA HAKKO KIRIN CO LTD [JP], et al
- US 2014044728 A1 20140213 - TAKAYANAGI SHIN-ICHIRO [JP], et al
- US 5811097 A 19980922 - ALLISON JAMES PATRICK [US], et al
- US 8552003 B2 20131008 - CHAREST MARK G [US], et al
- WO 2013184757 A1 20131212 - IRM LLC [US], et al
- WO 2006122806 A2 20061123 - NOVARTIS AG [CH], et al
- WO 2014085318 A1 20140605 - NOVARTIS AG [CH], et al
- WO 03064383 A2 20030807 - ARIAD GENE THERAPEUTICS INC [US], et al
- WO 2007046006 A2 20070426 - INST NAT SANTE RECH MED [FR], et al
- WO 2012040323 A2 20120329 - ALTOR BIOSCIEN CORP [US], et al
- US 8507222 B2 20130813 - WONG HING C [US], et al
- WO 2009002562 A2 20081231 - MARINEPOLYMER TECH INC [US], et al
- WO 2014066527 A2 20140501 - ADMUNE THERAPEUTICS LLC [US], et al
- WO 2015091853 A2 20150625 - ALLIGATOR BIOSCIENCE AB [SE]
- WO 03099340 A1 20031204 - UNIV CALIFORNIA [US]
- WO 2008070743 A2 20080612 - MEMGEN LLC [US], et al
- WO 2012027328 A2 20120301 - UNIV TEXAS [US], et al
- US 9006399 B2 20150414 - LIU YONG-JUN [US], et al
- US 7959925 B2 20110614 - WEINBERG ANDREW D [US], et al
- WO 2006121810 A2 20061116 - PROVIDENCE HEALTH SYSTEM [US], et al
- WO 2008051424 A2 20080502 - UNIV SOUTHAMPTON [GB], et al
- US 8481029 B2 20130709 - GLENNIE MARTIN JOHN [GB], et al
- WO 2012004367 A1 20120112 - ORGANON NV [NL], et al
- US 2011150892 A1 20110623 - THUDIUM KENT B [US], et al
- WO 2010019570 A2 20100218 - MEDAREX INC [US], et al
- WO 2014008218 A1 20140109 - BRISTOL MYERS SQUIBB CO [US]
- WO 2005073224 A2 20050811 - AMGEN INC [US]
- WO 2004045532 A2 20040603 - CHIRON CORP [US]
- WO 2005068503 A2 20050728 - CHIRON CORP [US], et al
- WO 2007121484 A2 20071025 - NOVARTIS AG [CH], et al
- WO 2006013107 A1 20060209 - NOVARTIS AG [CH], et al
- US 7807155 B2 20101005 - DI PADOVA FRANCO E [CH], et al
- US 8119131 B2 20120221 - DI PADOVA FRANCO E [CH], et al
- US 8617552 B2 20131231 - DI PADOVA FRANCO E [CH], et al
- EP 1776142 A1 20070425 - NOVARTIS AG [CH], et al
- WO 2014122613 A1 20140814 - NOVARTIS AG [CH], et al
- WO 2007070750 A1 20070621 - LILLY CO ELI [US], et al
- US 7838638 B2 20101123 - ALLAN BARRETT [US], et al
- US 8110191 B2 20120207 - ALLAN BARRETT [US], et al
- WO 2008054603 A2 20080508 - AMGEN INC [US], et al
- US 7767206 B2 20100803 - TOCKER JOEL [US], et al
- US 7786284 B2 20100831 - TOCKER JOEL [US], et al
- US 7833527 B2 20101116 - TOCKER JOEL [US], et al
- US 7939070 B2 20110510 - TOCKER JOEL [US], et al
- US 8435518 B2 20130507 - TOCKER JOEL [US], et al
- US 8545842 B2 20131001 - TOCKER JOEL [US], et al
- US 8790648 B2 20140729 - TOCKER JOEL [US], et al
- US 9073999 B2 20150707 - TOCKER JOEL [US], et al
- WO 0216436 A2 20020228 - NOVARTIS AG [CH], et al
- US 7446175 B2 20081104 - GRAM HERMANN [DE], et al
- EP 1313769 A2 20030528 - NOVARTIS AG [CH], et al
- WO 2010036380 A1 20100401 - INTELLIKINE INC [US], et al
- WO 2010006086 A2 20100114 - INTELLIKINE INC [US], et al
- WO 2009114870 A2 20090917 - INTELLIKINE INC [US], et al
- WO 2005113556 A1 20051201 - ICOS CORP [US], et al
- WO 2007084786 A1 20070726 - NOVARTIS AG [CH], et al
- WO 2010029082 A1 20100318 - NOVARTIS AG [CH], et al

- WO 2013124826 A1 20130829 - NOVARTIS AG [CH]
- US 8106163 B2 20120131 - HEUSSER CHRISTOPH [CH], et al
- WO 2015079417 A1 20150604 - NOVARTIS AG [CH], et al
- WO 2007070514 A1 20070621 - INCYTE CORP [US], et al
- WO 2013148228 A1 20131003 - ADVANCED CANCER THERAPEUTICS LLC [US]
- US 2015259420 A1 20150917 - TRIEBEL FRÉDÉRIC [FR], et al
- WO 2014022332 A1 20140206 - BRIGHAM & WOMENS HOSPITAL [US]
- WO 2010125571 A1 20101104 - TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD [IL], et al
- WO 2013082366 A1 20130606 - BRIGHAM & WOMENS HOSPITAL [US]
- US 2004047858 A1 20040311 - BLUMBERG RICHARD S [US], et al
- US 7132255 B2 20061107 - BLUMBERG RICHARD S [US]
- WO 9952552 A1 19991021 - BRIGHAM & WOMENS HOSPITAL [US]
- WO 2013054331 A1 20130418 - TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD [IL], et al
- US 2014271618 A1 20140918 - MARKEL GAL [IL], et al
- WO 03077914 A1 20030925 - ARRAY BIOPHARMA INC [US], et al
- WO 2005121142 A1 20051222 - JAPAN TOBACCO INC [JP], et al
- WO 2007004415 A1 20070111 - MURATA MANUFACTURING CO [JP], et al
- WO 2008024725 A1 20080228 - GENENTECH INC [US], et al
- WO 2009085983 A1 20090709 - GENENTECH INC [US], et al
- WO 2012177624 A2 20121227 - UNIV JOHNS HOPKINS [US], et al
- WO 2010029082 A1 20100318 - NOVARTIS AG [CH], et al
- WO 2010101849 A1 20100910 - IRM LLC [US], et al
- WO 9903854 A1 19990128 - NOVARTIS AG [CH], et al
- WO 03077914 A1 20030925 - ARRAY BIOPHARMA INC [US], et al
- US 8415355 B2 20130409 - BRAIN CHRISTOPHER THOMAS [US], et al
- US 8685980 B2 20140401 - BESONG GILBERT EBAI [DE], et al
- WO 2011025927 A1 20110303 - IRM LLC, et al
- US 8552002 B2 20131008 - DING QIANG [CN], et al
- WO 2005039549 A1 20050506 - NOVARTIS AG [CH], et al
- WO 2004005281 A1 20040115 - NOVARTIS AG [CH], et al
- WO 2010060937 A2 20100603 - NOVARTIS AG [CH], et al
- WO 2004072051 A1 20040826 - VERNALIS CAMBRIDGE LTD [GB], et al
- WO 2009141386 A1 20091126 - NOVARTIS AG [CH], et al
- WO 2010149755 A1 20101229 - NOVARTIS AG [CH], et al
- WO 2011076786 A1 20110630 - NOVARTIS AG [CH], et al
- WO 9749395 A1 19971231 - CIBA GEIGY AG [CH], et al
- US 4978672 A 19901218 - BOWMAN ROBERT M [US], et al
- WO 2013111105 A1 20130801 - NOVARTIS AG [CH]
- WO 2014072493 A1 20140515 - NOVARTIS AG [CH], et al
- WO 2007024945 A1 20070301 - NOVARTIS AG [CH], et al
- WO 2007131201 A2 20071115 - IRM LLC [US], et al
- WO 2010007120 A1 20100121 - NOVARTIS AG [CH], et al
- US 7867493 B2 20110111 - DAMIANO JASON [US], et al
- WO 2010026124 A1 20100311 - NOVARTIS AG [CH], et al
- WO 2011101409 A1 20110825 - NOVARTIS AG [CH], et al
- WO 2012022814 A1 20120223 - NOVARTIS AG [CH], et al
- WO 2014160160 A2 20141002 - NOVARTIS AG [CH], et al
- WO 03037347 A1 20030508 - NOVARTIS AG [CH], et al
- WO 0210192 A2 20020207 - NOVARTIS AG [CH], et al
- US 7473761 B2 20090106 - ALBERT RAINER [CH], et al
- WO 2009115562 A2 20090924 - NOVARTIS AG [CH], et al
- WO 2008073687 A2 20080619 - IRM LLC, et al
- WO 2010002655 A2 20100107 - IRM LLC, et al
- WO 2014141104 A1 20140918 - NOVARTIS AG [CH], et al
- WO 2013171639 A1 20131121 - NOVARTIS AG [CH], et al
- WO 2013171640 A1 20131121 - NOVARTIS AG [CH], et al
- WO 2013171641 A1 20131121 - NOVARTIS AG [CH], et al
- WO 2013171642 A1 20131121 - NOVARTIS AG [CH], et al
- WO 2014151616 A1 20140925 - NOVARTIS AG [CH], et al
- WO 2015066188 A1 20150507 - NOVARTIS AG [CH], et al
- HUARD ET AL., IMMUNOGENETICS, vol. 39, 1994, pages 213
- TRIEBEL ET AL., J. EXP. MED., vol. 171, 1990, pages 1393 - 1405
- HUANG, C ET AL., IMMUNITY, vol. 21, 2004, pages 503 - 513
- CAMISASCHI ET AL., J IMMUNOL, vol. 184, 2010, pages 6545 - 6551
- GAGLIANI ET AL., NAT MED, vol. 19, 2013, pages 739 - 746
- WORKMAN ET AL., J IMMUNOL, vol. 183, 2009, pages 3598 - 1891
- BAIXERAS ET AL., J. EXP. MED., vol. 176, 1992, pages 327 - 337
- HUARD ET AL., EUR. J. IMMUNOL., vol. 26, 1996, pages 1180 - 1186
- HUARD ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 3216 - 3221
- GROSS ET AL., J CLIN INVEST., vol. 117, 2007, pages 3383 - 3392
- BLACKBURN ET AL., NAT. IMMUNOL., vol. 10, no. 1, 2009, pages 29 - 37
- IOUZALEN ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 2885 - 2891
- WORKMAN, C. J.VIGNALI, D. A., J. IMMUNOL., vol. 174, 2005, pages 688 - 695
- TOMLINSON ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798
- NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
- E. MEYERSW. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17
- ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
- ALTSCHUL ET AL., NUCLEIC ACIDS RES, vol. 25, 1997, pages 3389 - 3402
- HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281
- VERHOEYAN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1043
- HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
- KABAT, E. A. ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, article "Sequences of Proteins of Immunological Interest"

- CHOTHIA, C ET AL., J MOL. BIOL., vol. 196, 1987, pages 901 - 917
- "Antibody Engineering Lab Manual", SPRINGER-VERLAG, article "Protein Sequence and Structure Analysis of Antibody Variable Domains"
- AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
- SALEH ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 32, 1990, pages 180 - 190
- LOBUGLIO ET AL., HYBRIDOMA, vol. 5, 1986, pages 5117 - 5123
- GARRAD ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1373 - 1377
- HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85
- GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734
- HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896
- CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
- GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580
- HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137
- BARB AS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982
- LONBERG, N ET AL., NATURE, vol. 368, 1994, pages 856 - 859
- GREEN, L.L. ET AL., NATURE GENET, vol. 7, 1994, pages 13 - 21
- MORRISON, S.L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1994, pages 6851 - 6855
- BRUGGEMAN ET AL., YEAR IMMUNOL, vol. 7, 1993, pages 33 - 40
- TUAILLON ET AL., PNAS, vol. 90, 1993, pages 3720 - 3724
- BRUGGEMAN ET AL., EUR J IMMUNOL, vol. 21, 1991, pages 1323 - 1326
- SUN ET AL., PNAS, vol. 84, 1987, pages 3439 - 3443
- LIU ET AL., J. IMMUNOL., vol. 139, 1987, pages 3521 - 3526
- NISHIMURA ET AL., CANC. RES., vol. 47, 1987, pages 999 - 1005
- WOOD ET AL., NATURE, vol. 314, 1985, pages 446 - 449
- SHAW ET AL., J. NATL. CANCER INST., vol. 80, 1988, pages 1553 - 1559
- MORRISON, S. L., SCIENCE, vol. 229, 1985, pages 1202 - 1207
- OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214
- JONES ET AL., NATURE, vol. 321, 1986, pages 552 - 525
- BEIDLER ET AL., J. IMMUNOL., vol. 141, 1988, pages 4053 - 4060
- COLCHER, D ET AL., ANN N Y ACAD SCI, vol. 880, 1999, pages 263 - 80
- REITER, Y, CLIN CANCER RES, vol. 2, 1996, pages 245 - 52
- INGLEFIELD ET AL., J INTERFERON CYTOKINE RES, vol. 28, no. 4, 2008, pages 253 - 63
- CAS, no. 1174395-19-7
- CAS , no. 951209-71-5
- CAS, no. 1013101-36-4
- PRESTA ET AL., CANCER RES, vol. 57, 1997, pages 4593 - 4599
- POPKOV ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 288, 2004, pages 149 - 164
- LEWITT ET AL., ANNALS OF NEUROLOGY, vol. 63, no. 3, 2008, pages 295 - 302
- ZAMARIN ET AL., FUTURE MICROBIOL, vol. 7, no. 3, 2012, pages 347 - 67
- ALEMANY ET AL., NATURE BIOTECHNOL, vol. 18, 2000, pages 723 - 27
- LOGOTHETIS, C.: "ASCO Educational", 2000, BOOK SPRING, article "Development of Cancer Vaccines", pages: 730 - 738
- TAMURA, Y ET AL., SCIENCE, vol. 278, 1997, pages 3023 - 3043
- DRANOFF ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 3539 - 43
- KIM, N ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013
- SUOT, RSRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588
- NESTLE, F ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332
- KUGLER, A ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336
- AMANN ET AL., J IMMUNOTHER, vol. 32, no. 5, 2009, pages 452 - 64
- KEIR ET AL., ANNU. REV. IMMUNOL., vol. 26, 2008, pages 677 - 704
- PARDOLL ET AL., NAT REV CANCER, vol. 12, no. 4, 2012, pages 252 - 64
- SHINOHARA T ET AL., GENOMICS, vol. 23, no. 3, 1994, pages 704 - 6
- FINGER LR ET AL., GENE, vol. 197, no. 1-2, 1997, pages 177 - 87
- HAMID, O ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, no. 2, 2013, pages 134 - 44
- RIDGE, J ET AL., NATURE, vol. 393, 1998, pages 474 - 478
- ADVANI ET AL., J CLIN ONCOL, vol. 27, no. 26, 2009, pages 4371 - 7
- KHUBCHANDANI ET AL., CURR OPIN INVESTIG DRUGS, vol. 10, no. 6, 2009, pages 579 - 87
- TAI ET AL., CANCER RES, vol. 65, no. 13, 2005, pages 5898 - 906
- ITO, N ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40
- WEINBERG, A ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169
- VITALE ET AL., CLIN CANCER RES, vol. 18, no. 14, 2012, pages 3812 - 21
- CHENFLIES, NAT REV IMMUNOL, vol. 13, no. 4, 2013, pages 227 - 42
- CAMISASCHI ET AL., J. IMMUNOL., vol. 184, no. 11, 2010, pages 6545 - 6551
- SCURR ET AL., MUCOSAL IMMUNOL., vol. 7, no. 2, 2014, pages 428 - 439
- XU ET AL., CANCER RES, vol. 74, no. 13, 2014, pages 3418 - 3428
- WOO ET AL., CANCER RES, vol. 72, no. 4, 2012, pages 917 - 27
- MILLER ET AL., EUR JDRUGMETAB PHARMACOKINET, vol. 39, 2014, pages 173 - 181
- MILLER ET AL., BMC PHARMACOLOGY AND TOXICOLOGY, vol. 16, no. 18, 2015
- ZARBOCK ET AL., BRITISH JOURNAL OF PHARMACOLOGY, 2008, pages 1 - 8
- NING ET AL., MOL CANCER THER, vol. 11, no. 6, 2012, pages 1353 - 64
- WU ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 6, 2013, pages 36
- SANDHAM ET AL., BIOORGMED CHEM, vol. 21, no. 21, 2013, pages 6582 - 91
- "Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC.
- BRIAN D. LEHMANN ET AL.: "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies", J CLIN INVEST, vol. 121, no. 7, 1 July 2011 (2011-07-01), pages 2750 - 2767, XP002690196, DOI: 10.1172/JCI45014
- STEIN RC: "Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment", ENDOCRINE-RELATED CANCER, vol. 8, no. 3, September 2001 (2001-09-01), pages 237 - 48, XP002964533, DOI: 10.1677/erc.0.0080237
- MARONE RCMILJANOVIC VGIESE BWYMAN MP: "Targeting phosphoinositide 3-kinase: moving towards therapy", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, no. 1, January 2008 (2008-01-01), pages 159 - 85, XP002569690
- MARKEL ET AL., J IMMUNOL, vol. 168, no. 6, 15 March 2002 (2002-03-15), pages 2803 - 10
- MARKEL ET AL., J IMMUNOL, vol. 177, no. 9, 1 November 2006 (2006-11-01), pages 6062 - 71
- MARKEL ET AL., IMMUNOLOGY, vol. 126, no. 2, February 2009 (2009-02-01), pages 186 - 200
- MARKEL ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 59, no. 2, February 2010 (2010-02-01), pages 215 - 30
- ORTENBERG ET AL., MOL CANCER THER, vol. 11, no. 6, June 2012 (2012-06-01), pages 1300 - 10
- STERN ET AL., J IMMUNOL, vol. 174, no. 11, 1 June 2005 (2005-06-01), pages 6692 - 701

- ZHENG ET AL., PLOS ONE, vol. 5, no. 9, 2 September 2010 (2010-09-02), pages e12529
- KEHRL, J ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050
- HOWARD, MO'GARRA, A, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200
- HAHNE, M ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365
- MELERO, I ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685
- HUTLOFF, A ET AL., NATURE, vol. 397, 1999, pages 262 - 266
- HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
- POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123
- MOKYR, M ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304
- COOK, R, JMANAG CARE PHARM, vol. 14, 2008, pages 19 - 25
- HALLETT, WHD ET AL., J OFAMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION, vol. 17, no. 8, 2011, pages 1133 - 145
- YI, Q, CANCER J, vol. 15, no. 6, 2009, pages 502 - 10
- RINI, B.I. ET AL., J. CLIN. ONCOL., vol. 28, no. 13, 2010, pages 2137 - 2143
- PAL. S.K. ET AL., CLIN. ADVANCES IN HEMATOLOGY & ONCOLOGY, vol. 12, no. 2, 2014, pages 90 - 99
- HUDES, G ET AL., N. ENGL. J. MED., vol. 356, no. 22, 2007, pages 2271 - 2281
- MOTZER, R.J. ET AL., LANCET, vol. 372, 2008, pages 449 - 456

#### Citation (search report)

- [ID] WO 2010019570 A2 20100218 - MEDAREX INC [US], et al
- [XPI] WO 2015138920 A1 20150917 - NOVARTIS AG [CH], et al
- [IDP] US 2015210769 A1 20150730 - FREEMAN GORDON JAMES [US], et al
- [I] KHALIL DANNY N ET AL: "The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy", IMMUNOTHERAPY OF CANCER IN: ADVANCES IN CANCER RESEARCH; ISSN 0065-230X; VOL. 128; [ADVANCES IN CANCER RESEARCH; ISSN 0065-230X; VOL], ACADEMIC PRESS, US, vol. 128, 1 January 2015 (2015-01-01), pages 1 - 68, XP009190991, ISSN: 0065-230X, DOI: 10.1016/BS.ACR.2015.04.010
- [ID] DREW M. PARDOLL: "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS CANCER, vol. 12, no. 4, 22 March 2012 (2012-03-22), pages 252 - 264, XP055150744, ISSN: 1474-175X, DOI: 10.1038/nrc3239
- [A] DMITRIY ZAMARIN ET AL: "Immune checkpoint modulation: Rational design of combination strategies", PHARMACOLOGY AND THERAPEUTICS., vol. 150, 10 January 2015 (2015-01-10), GB, pages 23 - 32, XP055218491, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2015.01.003
- [A] ROTHE M.D.C., SCHNORFEIL F.M., LICHTENEGGER F.S., SCHLÜTER M., NEITZ J., HIDDEMANN W., SUBKLEWE M.: "Enhancing dendritic cell-induced T-cell responses by immunomodulating molecules", 11 May 2015 (2015-05-11), pages 74, XP055280210, Retrieved from the Internet <URL:http://www.meeting.cimt.eu/cms/diskfiles/download/6/44f802fe32fbd40d17db6cbf0fc0c9d/CIMT\_Abstacts\_2015.pdf> [retrieved on 20160614]
- [T] HONG D S ET AL: "Phase I/II study of LAG525 +/- spartalizumab (PDR001) in patients (pts) with advanced malignancies", INTERNET CITATION, 4 May 2018 (2018-05-04), XP002784659, Retrieved from the Internet <URL:http://abstracts.asco.org/214/AbstView\_214\_222927.html> [retrieved on 20180911]

#### Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

#### DOCDB simple family (publication)

**WO 2017019894 A1 20170202; WO 2017019894 A8 20171109;** CY 1124299 T1 20220722; DK 3317301 T3 20210628; EP 3317301 A1 20180509; EP 3317301 B1 20210407; EP 3964528 A1 20220309; ES 2878188 T3 20211118; HR P20211058 T1 20211001; HR P20211058 T8 20211126; HU E055469 T2 20211129; LT 3317301 T 20210726; PL 3317301 T3 20211115; PT 3317301 T 20210709; SI 3317301 T1 20211029; US 2018340025 A1 20181129; US 2022153835 A1 20220519

#### DOCDB simple family (application)

**US 2016044545 W 20160728;** CY 211100603 T 20210705; DK 16757391 T 20160728; EP 16757391 A 20160728; EP 21165292 A 20160728; ES 16757391 T 20160728; HR P20211058 T 20210702; HU E16757391 A 20160728; LT 16757391 T 20160728; PL 16757391 T 20160728; PT 16757391 T 20160728; SI 201631247 T 20160728; US 201615747227 A 20160728; US 202117491420 A 20210930